Literature DB >> 24719151

Finding the 'ideal' regimen for fentanyl-based intravenous patient-controlled analgesia: how to give and what to mix?

Seokyung Shin1, Keoung Tae Min1, Yang Sik Shin1, Hyung Min Joo2, Young Chul Yoo1.   

Abstract

PURPOSE: This analysis was done to investigate the optimal regimen for fentanyl-based intravenous patient-controlled analgesia (IV-PCA) by finding a safe and effective background infusion rate and assessing the effect of adding adjuvant drugs to the PCA regimen.
MATERIALS AND METHODS: Background infusion rate of fentanyl, type of adjuvant analgesic and/or antiemetic that was added to the IV-PCA, and patients that required rescue analgesics and/or antiemetics were retrospectively reviewed in 1827 patients who underwent laparoscopic abdominal surgery at a single tertiary hospital.
RESULTS: Upon multivariate analysis, lower background infusion rates, younger age, and IV-PCA without adjuvant analgesics were identified as independent risk factors of rescue analgesic administration. Higher background infusion rates, female gender, and IV-PCA without additional 5HT₃ receptor blockers were identified as risk factors of rescue antiemetics administration. A background infusion rate of 0.38 μg/kg/hr [area under the curve (AUC) 0.638] or lower required rescue analgesics in general, whereas, addition of adjuvant analgesics decreased the rate to 0.37 μg/kg/hr (AUC 0.712) or lower. A background infusion rate of 0.36 μg/kg/hr (AUC 0.638) or higher was found to require rescue antiemetics in general, whereas, mixing antiemetics with IV-PCA increased the rate to 0.37 μg/kg/hr (AUC 0.651) or higher.
CONCLUSION: Background infusion rates of fentanyl between 0.12 and 0.67 μg/kg/hr may safely be used without any serious side effects for IV-PCA. In order to approach the most reasonable background infusion rate for effective analgesia without increasing postoperative nausea and vomiting, adding an adjuvant analgesic and an antiemetic should always be considered.

Entities:  

Keywords:  Analgesia; adjuvant drug; background infusion rate; fentanyl; patient-controlled

Mesh:

Substances:

Year:  2014        PMID: 24719151      PMCID: PMC3990071          DOI: 10.3349/ymj.2014.55.3.800

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  26 in total

Review 1.  Balanced analgesia: what is it and what are its advantages in postoperative pain?

Authors:  H Kehlet; M Werner; F Perkins
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Safety and efficacy of patient-controlled analgesia.

Authors:  P E Macintyre
Journal:  Br J Anaesth       Date:  2001-07       Impact factor: 9.166

Review 3.  Current and developing methods of patient-controlled analgesia.

Authors:  Pamela P Palmer; Ronald D Miller
Journal:  Anesthesiol Clin       Date:  2010-12

Review 4.  Improving postoperative pain management: what are the unresolved issues?

Authors:  Paul F White; Henrik Kehlet
Journal:  Anesthesiology       Date:  2010-01       Impact factor: 7.892

5.  Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain. A quantitative systematic review.

Authors:  B Walder; M Schafer; I Henzi; M R Tramèr
Journal:  Acta Anaesthesiol Scand       Date:  2001-08       Impact factor: 2.105

Review 6.  Treatment of acute postoperative pain.

Authors:  Christopher L Wu; Srinivasa N Raja
Journal:  Lancet       Date:  2011-06-25       Impact factor: 79.321

7.  Morphine at "sub-analgesic" background infusion rate plus low-dose PCA bolus control pain better and is as safe as twice a bolus-only PCA regimen: a randomized, double blind study.

Authors:  Ian White; Ronen Ghinea; Shmuel Avital; Shoshana Chazan; Oleg Dolkart; Avi A Weinbroum
Journal:  Pharmacol Res       Date:  2012-04-06       Impact factor: 7.658

8.  Morphine and its metabolites after patient-controlled analgesia: considerations for respiratory depression.

Authors:  Wai Johnn Sam; Sean C MacKey; Jörn Lötsch; David R Drover
Journal:  J Clin Anesth       Date:  2011-03       Impact factor: 9.452

9.  The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia.

Authors:  J W Song; E Y Park; J G Lee; Y S Park; B C Kang; Y H Shim
Journal:  Anaesthesia       Date:  2011-04       Impact factor: 6.955

10.  Risk assessment of postoperative nausea and vomiting in the intravenous patient-controlled analgesia environment: predictive values of the Apfel's simplified risk score for identification of high-risk patients.

Authors:  Shin Hyung Kim; Yang-Sik Shin; Young Jun Oh; Jeong Rim Lee; Sung Chan Chung; Yong Seon Choi
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

View more
  14 in total

1.  The usefulness of dual channel elastomeric pump for intravenous patient-controlled analgesia in geriatrics: a randomized, double-blind, prospective study.

Authors:  Chung Hun Lee; Soo Ah Cho; Seok Kyeong Oh; Sang Sik Choi; Myoung Hoon Kong; Young Sung Kim
Journal:  BMC Anesthesiol       Date:  2022-07-07       Impact factor: 2.376

2.  Comparison of Fentanyl plus different doses of dexamethasone with Fentanyl alone on postoperative pain, nausea, and vomiting after lower extremity orthopedic surgery.

Authors:  Ghodrat Akhavan Akbari; Ali Mohammadian Erdi; Farzad Nabipour Asri
Journal:  Eur J Transl Myol       Date:  2022-04-29

3.  The evaluation of implementing smart patient controlled analgesic pump with a different infusion rate for different time duration on postoperative pain management.

Authors:  Saeyoung Kim; Younghoon Jeon; Hyeonjun Lee; Jung A Lim; Sungsik Park; Si Oh Kim
Journal:  J Dent Anesth Pain Med       Date:  2016-12-31

4.  Comparison of analgesic efficacy of oxycodone and fentanyl after total hip replacement surgery: A randomized controlled trial.

Authors:  Mi Kyeong Kim; Sang Eun Ahn; Eunsil Shin; Sung Wook Park; Jeong-Hyun Choi; Hee Yong Kang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

5.  Effect of Fentanyl-Based Intravenous Patient-Controlled Analgesia with and without Basal Infusion on Postoperative Opioid Consumption and Opioid-Related Side Effects: A Retrospective Cohort Study.

Authors:  Haesun Jung; Kook Hyun Lee; YoungHyun Jeong; Kang Hee Lee; Susie Yoon; Won Ho Kim; Ho-Jin Lee
Journal:  J Pain Res       Date:  2020-11-24       Impact factor: 3.133

6.  The efficacy of ultrasound-guided erector spinae plane block after mastectomy and immediate breast reconstruction with a tissue expander: a randomized clinical trial.

Authors:  Sukhee Park; Joohyun Park; Ji Won Choi; Yu Jeong Bang; Eun Jung Oh; Jiyeon Park; Kwan Young Hong; Woo Seog Sim
Journal:  Korean J Pain       Date:  2021-01-01

7.  Virtual reality as a non-pharmacologic analgesic for fasciotomy wound infections in acute compartment syndrome: a case report.

Authors:  Ryo Esumi; Ayumu Yokochi; Motomu Shimaoka; Eiji Kawamoto
Journal:  J Med Case Rep       Date:  2020-04-14

8.  Continuous Fentanyl Background Infusion Regimen Optimised by Patient-Controlled Analgesia for Acute Postoperative Pain Management: A Randomised Controlled Trial.

Authors:  Jihoon Hwang; Sang Kee Min; Yun Jeong Chae; Gang Mee Lim; Han Bum Joe
Journal:  J Clin Med       Date:  2020-01-13       Impact factor: 4.241

9.  Postoperative Pain and Intravenous Patient-Controlled Analgesia-Related Adverse Effects in Young and Elderly Patients: A Retrospective Analysis of 10,575 Patients.

Authors:  Jae Chul Koh; Jinae Lee; So Yeon Kim; Sumin Choi; Dong Woo Han
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

10.  Comparison of the Efficacy and Safety of a Pharmacokinetic Model-Based Dosing Scheme Versus a Conventional Fentanyl Dosing Regimen For Patient-Controlled Analgesia Immediately Following Robot-Assisted Laparoscopic Prostatectomy: A Randomized Clinical Trial.

Authors:  Seok-Joon Jin; Hyeong-Seok Lim; Youn-Ju Kwon; Se-Ung Park; Jung-Min Yi; Ji-Hyun Chin; Jai-Hyun Hwang; Young-Kug Kim
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.